Huya Bioscience partners with Japanese company to develop T-cell lymphoma therapy
Eisai Co. Ltd., a Japanese pharmaceutical company, has signed a licensing agreement with San Diego, California-based Huya Bioscience International LLC for the development and marketing of HBI-8000. The treatment is an oral histone deacetylase (HDAC) inhibitor already being used in third phase clinical trials in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.
A Phase I clinical study of HBI-8000, which studies have shown can regulate tumor cell growth, was recently completed in the U.S. The study focused on the effects of HBI-8000 on solid tumors.
HBI-8000 works by blocking the catalytic pocket of Class I HDACs. It is an oral therapy that has been shown to manage tumor growth in a number of ways. Clinical trials have used the drug in the treatment of solid tumors; it is currently being tested on non-Hodgkin's lymphoma in Japan.
Organizations in this story
Eisai 100 Tice Blvd. Woodcliff Lake, NJ - 07677